You are here: Industry Insights > Oxford BioTherapeutics

News List

Boehringer expands oncology partnership with Oxford BioTherapeutics pharmaceutical-technology
October 16, 2020
Boehringer Ingelheim has announced the expansion of its partnership with UK-based Oxford BioTherapeutics (OBT) to discover novel selective targets for strategic cancer indications to deliver treatments for cancer patients.
Oxford BioTherapeutics Receives IND Clearance for OBT076 americanpharmaceuticalreview
December 24, 2018
Oxford BioTherapeutics has received US Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for OBT076.....
Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m pharmafile
December 13, 2018
Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in a deal worth more than $450 million.
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million expressbpd
December 11, 2018
WuXi Biologics and Oxford BioTherapeutics Ltd. announced the expansion of their strategic and innovative immuno-oncology (IO) alliance...
Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans firstwordpharma
February 10, 2017
Oxford BioTherapeutics ("OBT") announced a significant strengthening of its oncology focused Board of Directors with the appointment of Bernd Seizinger M.D., Ph.D. as Chairman and Jean-Pierre Bizzari, M.D. as a non-executive director.